Search Results

Press Releases

SetPoint Medical Announces Late-Breaking Data from RESET-RA Study at ACR Convergence 2024

November 18, 2024

·

5 min read

Press Releases

SetPoint Medical Announces Filing of Premarket Approval (PMA) Application to the U.S. Food and Drug Administration (FDA) for Novel Neuroimmune Modulation Device for the Treatment of Rheumatoid Arthritis

December 9, 2024

·

2 min read

FDA

SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis

SetPoint Medical Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).

March 13, 2024

·

4 min read

Press Releases

SetPoint Medical Receives FDA’s IDE Approval for U.S. Pilot Study of Neuroimmune Modulation Platform in Adults with Relapsing-Remitting Multiple Sclerosis

October 2, 2024

·

3 min read

Policy

SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has been accepted into the Total Product Life Cycle Advisory Program Pilot from the U.S. Food and Drug Administration for the development of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis.

March 21, 2024

·

3 min read

Press Releases

SetPoint Medical Announces Positive Topline Results from Landmark RESET-RA Study Evaluating Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis

July 10, 2024

·

5 min read

Business

SetPoint Medical Appoints Rohan Seth as Chief Financial Officer

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the appointment of Rohan Seth as Chief Financial Officer.

June 12, 2023

·

2 min read

Biotech Beach

SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn’s Disease in Journal of Crohn’s and Colitis

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in the Journal of Crohn’s and Colitis.

October 3, 2023

·

3 min read

Biotech Beach

SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced an $80 million preferred stock financing co-led by new investors Norwest Venture Partners and Viking Global Investors.

January 19, 2023

·

3 min read

Biotech Bay

SetPoint Medical Announces Expanded $65M Credit Facility to Support Development of the Company’s Novel Platform for Rheumatoid Arthritis

SetPoint Medical today announced a senior secured term loan facility of up to $65 million from Runway Growth Capital LLC (“Runway”), a leading provider of growth loans to both venture and non-venture backed companies.

January 19, 2023

·

3 min read